Topic: respiratory syncytial virus
Critics have blasted AstraZeneca’s rummage-sale strategy as unsustainable, but CEO Pascal Soriot says it's vital for bottom-line growth.
Chasing a $6 billion market opportunity, Bavarian Nordic reports that a dose of its universal RSV vaccine can elicit a significant immune response.
The FDA fast-tracked Novavax's RSV candidate for the protection of older adults.
Bavarian Nordic announced today positive topline results from a Phase I trial of its RSV candidate and revealed a $100 million contract to supply HHS’ BARDA with its smallpox vaccine.